

Hindustan Unilever

Estimate change	↔
TP change	↔
Rating change	↔

Motilal Oswal values your support in the Asiamoney Brokers Poll 2020 for India Research, Sales and Trading team. We [request your ballot](#).



Bloomberg	HUVR IN
Equity Shares (m)	2,345
M.Cap.(INRb)/(USDb)	5444.8 / 73.2
52-Week Range (INR)	2614 / 1660
1, 6, 12 Rel. Per (%)	2/21/36
12M Avg Val (INR M)	7346

Financials & Valuations (INR b)

Y/E March	2019	2020	2021E	2022E
Sales	382.2	387.9	442.4	515.9
Sales Gr. (%)	10.7	1.5	14.1	16.6
EBITDA	86.4	96.0	112.5	138.1
EBITDA mrg. (%)	22.6	24.8	25.4	26.8
Adj. PAT	60.8	67.4	80.5	103.6
Adj. EPS (INR)	28.1	31.2	34.4	44.2
EPS Gr. (%)	14.7	11.1	10.0	28.6
BV/Sh.(INR)	35.4	37.2	56.4	58.6

Ratios

RoE (%)	82.5	86.0	75.8	76.8
RoCE (%)	119.1	119.8	103.4	103.5
Payout (%)	94.8	96.2	101.9	99.6

Valuations

P/E (x)	82.6	74.3	67.5	52.5
P/BV (x)	65.5	62.4	41.1	39.5
EV/EBITDA (x)	57.7	51.6	47.3	38.4
Div. Yield (%)	0.9	1.1	1.5	1.9

Shareholding pattern (%)

As On	Jun-20	Mar-20	Jun-19
Promoter	61.9	67.2	67.2
DII	8.3	6.7	6.9
FII	14.8	12.1	12.1
Others	15.0	14.1	13.8
FII Includes depository receipts			

CMP: INR2,319 TP: INR2,550 (+10%) Buy

Decent beat in challenging quarter; Scale benefits and GSK drive margin beat

Brief view on results and stock

- Hindustan Unilever (HUVR) reported 5% beat on sales and ~10% beat on EBITDA and PAT v/s our estimates.
- The outlook is gradually improving, with the discretionary part of the portfolio (15% of sales) gradually seeing recovery. In a period of relative normalcy, HUVR (as has been the case in recent years) is likely to report superior earnings growth, which has led us to **maintain a BUY rating**.

Beat on all fronts

- HUVR's reported net sales grew 4.4% YoY to INR105.6b** in 1QFY21 (est.: INR100.1b). EBITDA edged down 0.1% YoY to INR26.4b (est.: 10.3% decline to INR23.7b), and PBT de-grew 1.1% YoY to INR25.3b (est.: INR23.2b). On the other hand PAT (bei) was up 7% YoY to INR18.7b (est.: INR17.2b). Gross margins stood at 51.8% (220bp contraction YoY), while EBITDA margins contracted by 110bp YoY to 25%.
- Underlying domestic Consumer business'** sales declined 7% YoY in 1QFY21, led by **underlying volume decline of 8% YoY (~4% growth including GSKCH** v/s est. 1.5% volume growth YoY).
- Segmental performance:** Revenue was down 2.1% YoY for Home Care (HC; 32% of sales for 1QFY21), down 12% YoY for Personal Care (PC; 38% of sales), and up 51.7% YoY for Food & Refreshments (F&R; 28% of sales). The segmental EBIT margin up by 20bp YoY for F&R, but down by 140bp/150bp for HC/PC.
- The scheme of arrangement for the transfer of balance in General Reserves of INR21.9b** to the P&L A/c was approved by its Shareholders in 2016. Subsequently, the scheme was sanctioned by the Hon'ble National Company Law Tribunal, Mumbai Bench – vide its order dated 30th Aug'18. The Board approved the distribution of the Reserves to its Shareholders by means of a Special Dividend of INR9.50/share.
- GSKCH merger impact:** The GlaxoSmithKline Consumer Healthcare (GSKCH) merger from 1st April resulted in: (1) 4.4% sales growth YoY v/s the 7% base business sales decline; (2) positive contribution to EBITDA margins (+60bp, reducing YoY margin decline to 110bp) despite integration costs impacting margins; (3) reported revenue growth of 5% YoY, which is healthy given: a) the impact of the lockdown and b) that the merger happened only from 1st April 2020, indicating execution was very good at this early stage. The pace of sales growth is not only likely to be better going forward, but synergies and lower integration costs are likely to positively impact overall margins further.

Highlights from management commentary

- 80% of the portfolio (non-discretionary) grew 6% YoY in the June quarter despite the lockdown impact; among the rest of the businesses, Skin Care is showing signs of recovery.

- GSKCH – As there are no royalty costs, the company was able to offset the transition costs in the GSKCH business.
- Rural demand outlook – A good harvest, government spend, and good monsoon are leading to higher growth.

Valuation and view

- Changes to the model have resulted in a ~2% increase in FY21/FY22 EPS. As mentioned in [our Corner Office note](#) and [detailed note on the Annual Report](#), the structural and near-term investment case for HUVR remains strong.
- The company's earnings growth has gained further momentum in recent years (17% EPS CAGR in the past three years v/s ~12% CAGR over 10 years). This is particularly impressive given the weak mid-single-digit earnings growth posted by (much smaller) peers in recent years. HUVR's best-of-breed analytics and execution ability (exhibited by the successful implementation of the WIMI strategy, cost-saving plans, herbals, etc.) are key factors driving the pace of earnings growth.
- The scale of HUVR's P&L v/s peers offers the company significant levers for superior management of costs even beyond what was already witnessed in 1QFY21. Even in FY20, the company managed to carve out as much as 7% of sales on cost savings.
- We remain positive on HUVR from a medium-term perspective, encouraged by: a) robust earnings growth potential beyond the near term owing to its portfolio and execution strengths and b) significant synergies in FY22E as a result of GSKCH. These factors suggest premium multiples are likely to sustain. Valuing the company at 55x Jun'22 merged EPS, we arrive at **TP of INR2,550, implying a 10% upside.**

Quarterly performance (Standalone)

Y/E March	FY20				FY21						FY21	Var.
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE	FY20	FY21E	1QE	
Domestic volume gr. (%)	5.0	5.0	5.0	-7.0	4.0	10.5	14.0	27.0	2.0	13.9	1.5	
Net sales	101.1	98.5	98.1	90.1	105.6	109.2	112.6	115.0	387.9	442.4	100.1	5.4%
YoY change (%)	6.6	6.7	2.6	-9.4	4.4	10.8	14.8	27.6	1.5	14.1	-1.0	
Gross Profit	54.7	53.7	53.2	48.4	54.7	57.2	59.5	62.1	209.9	233.5	53.5	
Margin %	54.0	54.5	54.2	53.7	51.8	52.4	52.8	54.0	54.1	52.8	53.5	
EBITDA	26.5	24.4	24.5	20.7	26.4	27.3	29.3	29.4	96.0	112.5	23.7	11.4%
YoY change (%)	17.6	21.0	19.5	-11.0	-0.1	11.6	19.9	42.6	11.1	17.1	-10.3	
Margins (%)	26.2	24.8	24.9	22.9	25.0	25.0	26.0	25.6	24.8	25.4	23.7	
Depreciation	2.1	2.4	2.3	2.6	2.4	2.6	3.0	2.8	9.4	10.8	2.4	
Interest	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.2	1.1	1.0	0.2	
Other income	1.5	1.8	1.4	2.7	1.6	2.2	2.2	2.3	7.3	8.3	2.1	
PBT	25.6	23.6	23.3	20.5	25.3	26.6	28.3	28.7	92.9	108.8	23.2	9.0%
Tax	8.1	5.2	6.4	5.8	6.6	7.1	7.9	8.0	25.5	28.3	6.0	
Rate (%)	31.5	22.2	27.4	28.3	25.9	26.7	27.8	28.0	27.4	26.0	26.0	
PAT bei	17.5	18.3	16.9	14.7	18.7	19.5	20.4	20.6	67.4	80.5	17.2	9.1%
YoY change (%)	11.7	20.4	20.7	-7.6	7.0	6.5	20.7	22.1	10.9	19.4	-1.9	
Reported Profit	17.6	18.5	16.2	15.2	18.8	19.5	20.4	20.6	67.4	80.5	17.2	

E: MOFSL Estimates

Key Performance Indicators

Y/E March	FY20				FY21			
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE
2Y average growth %								
Volumes	8.5	7.5	7.5	0.0	4.5	7.8	9.5	10.0
Sales	8.9	8.9	6.9	0.0	5.5	8.8	8.7	9.1
EBITDA	19.1	20.5	20.6	1.2	8.7	16.3	19.7	15.8
PAT	16.5	21.8	18.8	2.6	9.4	13.4	20.7	7.2
% sales								
COGS	46.0	45.5	45.8	46.3	48.2	47.6	47.2	46.0
Staff cost	4.5	4.4	4.6	3.9	5.6	4.1	4.1	6.8
Advertising and Promotion	11.5	12.2	11.9	12.9	7.5	11.3	10.9	5.8
Others	11.9	13.2	12.8	13.9	13.6	12.1	11.7	15.7
Depreciation	2.1	2.4	2.4	2.8	2.3	2.4	2.7	2.4
YoY change %								
COGS	6.5	1.1	1.6	-12.1	9.4	15.8	18.4	26.9
Staff cost	-0.2	-0.4	-0.2	-0.1	1.1	-0.3	-0.5	2.9
Advertising and Promotion	-0.7	0.2	-0.6	1.8	-3.9	-0.9	-0.9	-7.1
Others	-1.5	-0.2	-2.3	0.2	1.7	-1.0	-1.1	1.8
Other income	8.9	-41.0	32.1	125.4	6.1	23.0	60.0	-15.0
EBIT	14.5	16.8	15.7	-17.2	-1.3	11.7	18.8	47.2

E: MOFSL Estimates

Exhibit 1: Segmental performance

Segment Revenue INR b	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20	1QFY21
Home Care	30.8	31.5	35.0	34.7	33.7	34.6	33.5	33.9
Personal Care	43.2	45.4	43.9	45.9	45.4	44.1	38.0	40.4
Foods & Refreshments	17.0	17.3	19.2	19.5	18.5	18.7	17.9	29.6
Others	1.3	1.4	1.3	1.1	0.9	0.8	0.7	1.7
Net Segment Revenue	92.3	95.5	99.5	101.1	98.5	98.0	90.1	105.6
Growth YoY %								
Home Care	12.4	14.8	12.9	10.1	9.4	9.8	-4.3	-2.1
Personal Care	10.4	11.0	7.3	4.1	5.3	-2.8	-13.5	-12.0
Foods & Refreshments	11.7	9.9	10.4	9.2	8.4	7.9	-6.7	51.7
Others	4.7	-23.5	-18.3	-26.2	-32.1	-47.6	-46.3	55.5
Net Segment Revenue	11.2	11.3	9.3	6.6	6.7	2.6	-9.4	4.4
Salience %								
Home Care	33.4	32.9	35.2	34.3	34.2	35.2	37.2	32.1
Personal Care	46.7	47.5	44.2	45.4	46.1	45.0	42.2	38.2
Foods & Refreshments	18.5	18.1	19.3	19.3	18.7	19.0	19.8	28.0
Others	1.5	1.5	1.3	1.1	0.9	0.8	0.8	1.6
Total Segment Revenue	100	100	100	100	100	100	100	100
Segment Results (EBIT) - INR b								
Home Care	5.0	4.5	6.2	7.0	6.0	6.3	6.4	6.4
Personal Care	11.4	11.7	12.2	13.6	13.2	12.5	9.5	11.3
Foods & Refreshments	3.0	2.6	3.5	3.8	2.9	3.3	2.3	5.8
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5
Total Segment Results	19.3	18.7	21.9	24.4	22.1	22.1	18.1	24.0
PBT	21.5	19.5	22.3	25.6	23.1	22.3	19.9	24.1
Growth YoY (%)								
Home Care	29.8	26.0	21.1	16.1	19.7	41.0	2.7	-8.9
Personal Care	20.0	15.7	8.3	16.9	15.6	7.5	-22.5	-16.5
Foods & Refreshments	27.7	51.7	20.1	13.5	-0.3	28.0	-35.0	53.6
Others	-133.3	0.0	0.0	-200.0	0.0	-33.3	100.0	2350.0
Total Segment Results	24.2	22.2	13.4	16.3	14.2	18.4	-17.2	-1.5
Salience %								
Home Care	23.1	22.9	27.8	27.3	25.8	28.2	31.9	26.4
Personal Care	52.9	59.7	54.8	53.0	57.0	56.2	47.4	47.0
Foods & Refreshments	13.7	13.4	15.5	14.8	12.7	15.0	11.3	24.1
Others	0.1	-0.2	0.1	0.1	0.1	-0.1	0.2	2.0
Total Segment Results	89.8	95.8	98.2	95.1	95.6	99.3	90.9	100.0
PBT	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Segmental EBIT margin (%)								
Home Care	16.1	14.2	17.7	20.2	17.7	18.2	19.0	18.8
Personal Care	26.4	25.7	27.8	29.6	28.9	28.4	24.9	28.1
Foods & Refreshments	17.3	15.1	18.1	19.4	15.9	17.9	12.6	19.7
Others	1.5	-2.1	1.5	1.8	2.2	-2.7	5.6	28.7
Total	20.9	19.6	22.0	24.1	22.4	22.6	20.1	22.7
EBIT margin change YoY (%)								
Home Care	2.2	1.3	1.2	1.0	1.5	4.0	1.3	-1.4
Personal Care	2.1	1.0	0.3	3.2	2.6	2.7	-2.9	-1.5
Foods & Refreshments	2.2	4.2	1.5	0.7	-1.4	2.8	-5.5	0.2
Others	6.2	-0.5	0.3	3.2	0.7	-0.6	4.1	26.8
Total	2.2	1.7	0.8	2.0	1.5	3.0	-1.9	-1.4

Source: Company, MOFSL



Conference call highlights

Key highlights

- HUVR believes it has made good progress over the last few months, with satisfying results. Its dynamic response to a changing environment has supported its performance.
- The merger with GSKCH could not have come at a better time from the perspective of introducing an in-home consumption and immunity building product. It witnessed sound growth of 5% v/s the corresponding quarter last year.
- 8% volume decline was reported on a like-to-like basis on 7% sales decline.
- 80% of the portfolio (non-discretionary) has grown at 6%.
- HUVR was at a 70% operational level in April, which was better in May.
- June sales growth was in the mid-single digits, partly due to the normalization of pipelines; if not for this, growth would likely have been flattish.
- With more lockdowns the company advised caution on extrapolating the growth being reported in the month of June. At the same time, a heightened sense of hygiene is likely to persist.
- Rural demand outlook – A good harvest, government spend, and a good monsoon are leading to higher growth.
- Urban growth has also been affected by the lockdown.
- HUVR maintains that rural is witnessing green shoots and is not yet a full-fledged revival even as performance vs. urban is likely to be better.

Impact on discretionary businesses

- Skin Care, Color Cosmetics, and Deodorants (15% of portfolio) declined 45% YoY in the June quarter. Skin Care showed signs of improvement in June and is likely to do better going forward.
- The Out-of-Home business (5% of the portfolio, mainly Ice-creams and Water Purifiers) declined 69% YoY and is likely to remain weak going forward.

Glow & Lovely (formerly Fair & Lovely)

- HUVR is highly confident of not only retaining existing customers but also attracting new ones.
- Despite the repositioning more than a year ago, growth has been healthy.

Other points

- Production capacity was rapidly increased by 100x in Sanitizers and by 5x in Hand Washes to meet demand.
- The base business reported a 170bp EBITDA margin decline, while GSK added 60bp to margins, implying 110bp margin decline on a merged basis.
- HUVR's adverse portfolio mix for the quarter impacted gross margins. The mix would not be as bad going forward.
- GSKCH – Since there are no royalty costs now they were able to offset the transition costs in the GSKCH business.
- COVID-19-related sanitization costs would be lower going forward, and some of the GSKCH integration also be lower.

- HUVR is taking price increases in Tea due to higher commodity costs. In Detergents, the company is looking to pass on the benefits of lower crude costs to boost growth.
- The number of SKUs is still at 50% of pre-COVID-19 levels, but the company is looking to prune 20% of the tail anyway.

Special Dividend

- The Scheme of Arrangement for the transfer of balance in General Reserves of INR21.9b to the P&L A/c was approved by its Shareholders in 2016. Subsequently, the scheme was sanctioned by the Hon'ble National Company Law Tribunal, Mumbai Bench – vide its order dated 30th August 2018. The Board approved the distribution of the Reserves to its Shareholders by means of a Special Dividend of INR9.50/share.

Key exhibits

Exhibit 2: Impact on LTL domestic sales lower than expected in tough quarter




Exhibit 3: Underlying volume decline by 7% YoY in 1QFY21 (~4% growth including GSKCH v/s est. 1.5% growth YoY)





Exhibit 4: Underlying volumes decline on two-year average basis



- **Higher operating expenses as a percentage of sales** (up 170bp YoY to 13.6%), lower ad spends (down 390bp YoY to 7.5%), and higher staff cost (up 110bp YoY to 5.6%) led to EBITDA margin contraction of 110bp YoY to 25%.








Exhibit 5: Realization growth of 1% in 1QFY21**Exhibit 6: Gross margins contract by 220bp YoY to 51.8%****Exhibit 7: A&P spends down 390bp YoY...****Exhibit 8: ...Employee expenses up 110bp YoY...****Exhibit 9: ...Other expenses up 170bp YoY...****Exhibit 10: ...leading to EBITDA margin contraction of 110bp YoY**

Exhibit 11: Portfolio snapshot amid COVID-19 crisis



*% Portfolio Contribution

Source: Company, MOFSL

Valuation and view

Why has HUVR been a strong wealth generator in the last 10 years?

- A newfound nimbleness in response to raw material cost and competitive stimuli has reinvigorated earnings growth to the strong double digits over this period. Best-of-breed analytics have further boosted growth.
- The strong execution of its “Winning in Many India (WIMI)’ strategy has meant that Central India growth at 1.5x the base growth. Execution in Herbal Products and more recently on acquisitions has also been remarkable.
- Its focus on premiumization, particularly evident in Detergents and Tea, has meant that even these highly penetrated and large categories have grown smartly. This, in addition to a rigorous focus on cost savings, has resulted in an unprecedented EBITDA margin improvement of over 920bp YoY over the past 10 years.
- Consequently, despite being the largest giant in the Consumer space, its 10-year sales/EBITDA/PAT growth has been healthy at 8.1%/13.3%/12.4% CAGRs. The last five-year and three-year performances have been even more impressive on the EBITDA/PAT front at CAGRs of 13.0%/13.1% and 16.7%/16.6%, respectively. This is particularly impressive given the weak earnings growth posted by peers in recent years.

Our investment case for HUVR

- Changes to the model have led to a ~2% increase in FY21/FY22 EPS. As mentioned in [our Corner Office note](#) and [detailed note on the Annual Report](#), the structural and near-term investment case for HUVR remains strong.
- HUVR’s earnings growth has gained further momentum in recent years (17% EPS CAGR in the past three years v/s ~12% CAGR over 10 years). This is particularly impressive given the weak mid-single-digit earnings growth posted by (much smaller) peers in recent years. HUVR’s best-of-breed analytics and execution

ability (exhibited by the successful implementation of the WIMI strategy, cost-saving plans, herbals, etc.) are key factors driving the pace of earnings growth.


- The scale of HUVR's P&L vis-à-vis peers offers the company significant levers for the superior management of costs even beyond what was already witnessed in 1QFY21. Even in FY20, the company managed to carve out as much as 7% of sales on cost savings.
- We remain positive on HUVR from a medium-term perspective due to: a) robust earnings growth potential beyond the near term owing to its portfolio and execution strengths, and b) significant synergies in FY22E as a result of GSKCH. These factors suggest premium multiples are likely to sustain. Valuing the company at 55x Jun'22 merged EPS, we arrive at TP of INR2,550, implying a 10% upside.

Exhibit 12: Changes to model lead to 1.6%/1.8% increase in FY21/FY22 EPS

	New		Old		Change	
	FY21E	FY22E	FY21E	FY22E	FY21E	FY22E
Sales	442.4	515.9	442.4	515.9	0.0%	0.0%
EBITDA	112.5	138.1	109.5	135.7	2.7%	1.8%
PAT	80.5	103.6	79.2	101.7	1.6%	1.8%


Source: Company, MOFSL

Exhibit 13: HUVR P/E (x)



Source: Bloomberg, Company, MOFSL

Exhibit 14: Consumer sector P/E (x)



Source: Bloomberg, Company, MOFSL

Financials and valuations

Income Statement								(INR m)
Y/E March	FY15	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
Net Sales	3,01,705	3,04,990	3,12,980	3,39,260	3,76,600	3,82,730	4,37,187	5,10,410
Other Oper. Income	6,351	5,619	5,920	5,990	5,640	5,120	5,222	5,484
Total Revenue	3,08,056	3,10,609	3,18,900	3,45,250	3,82,240	3,87,850	4,42,409	5,15,893
Change (%)	9.9	0.8	2.7	8.3	10.7	1.5	14.1	16.6
COGS	1,56,236	1,53,053	1,56,850	1,62,320	1,79,600	1,77,930	2,08,906	2,28,767
Gross Profit	1,51,821	1,57,556	1,62,050	1,82,930	2,02,640	2,09,920	2,33,503	2,87,127
Gross Margin (%)	49.3	50.7	50.8	53.0	53.0	54.1	52.8	55.7
Operating Exp	99,738	1,00,070	1,01,580	1,10,170	1,16,270	1,13,920	1,21,048	1,49,033
% of sales	32.4	32.2	31.9	31.9	30.4	29.4	27.4	28.9
EBIDTA	52,082	57,486	60,470	72,760	86,370	96,000	1,12,455	1,38,094
Change (%)	16.4	10.4	5.2	20.3	18.7	11.1	17.1	22.8
Margin (%)	16.9	18.5	19.0	21.1	22.6	24.8	25.4	26.8
Depreciation	2,867	3,208	3,960	4,780	5,240	9,380	10,846	11,593
Int. and Fin. Charges	168	150	220	200	280	1,060	1,047	1,068
Other Income - Recurring	6,184	5,640	5,260	5,690	6,640	7,330	8,276	13,029
Profit before Taxes	55,231	59,769	61,550	73,470	87,490	92,890	1,08,838	1,38,461
Change (%)	15.1	8.2	3.0	19.4	19.1	6.2	17.2	27.2
Margin (%)	18.3	19.6	19.7	21.7	23.2	24.3	24.9	27.1
Tax	19,060	18,160	18,650	21,480	27,480	23,940	28,298	34,851
Deferred Tax	-338	-70	410	-1,000	-790	1,520	0	0
Tax Rate (%)	33.9	30.3	31.0	27.9	30.5	27.4	26.0	25.2
Profit after Taxes	36,510	41,679	42,490	52,990	60,800	67,430	80,540	1,03,611
Change (%)	2.7	14.2	1.9	24.7	14.7	10.9	19.4	28.6
Margin (%)	12.1	13.7	13.6	15.6	16.1	17.6	18.4	20.3
Non-rec. (Exp)/Income	6,643	-310	2,410	-620	-440	-50	0	0
Reported PAT	43,153	41,369	44,900	52,370	60,360	67,380	80,540	1,03,611

Balance Sheet								(INR m)
Y/E March	FY15	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
Share Capital	2,164	2,164	2,164	2,164	2,165	2,160	2,345	2,345
Reserves	35,084	60,630	62,740	68,590	74,430	78,150	1,29,904	1,35,137
Capital Employed	37,248	62,794	64,904	70,754	76,595	80,310	1,32,249	1,37,482
Net Fixed Assets	24,575	29,147	40,240	41,420	43,430	50,560	40,714	34,121
Capital WIP	4,790	3,860	2,030	4,300	3,730	5,130	5,256	5,256
Investment in Subsidiaries	6,541	3,130	2,540	2,540	2,540	2,500	2,500	2,500
Current Investments	26,238	24,670	35,250	28,570	26,950	12,500	13,500	14,500
Deferred Charges	1,960	1,680	1,600	2,550	3,390	2,610	3,749	3,749
Curr. Assets, L&A	72,236	76,509	65,850	92,110	98,615	1,22,720	2,13,804	2,41,626
Inventory	26,027	25,284	23,620	23,590	24,220	26,360	34,670	40,412
Account Receivables	7,829	10,645	9,280	11,470	16,730	10,460	18,697	21,787
Cash and Bank Balance	25,376	27,590	16,710	33,730	36,880	50,170	1,15,623	1,33,010
Others	13,005	12,990	16,240	23,320	20,785	35,730	44,814	46,417
Curr. Liab. and Prov.	99,093	76,202	82,606	1,00,736	1,02,060	1,15,710	1,47,275	1,64,270
Account Payables	48,515	54,980	60,060	70,130	70,700	73,990	90,935	1,04,337
Other Liabilities	29,828	12,382	13,826	16,376	15,860	25,560	32,452	34,075
Provisions	20,749	8,840	8,720	14,230	15,500	16,160	23,888	25,858
Net Current Assets	-26,857	307	-16,756	-8,626	-3,445	7,010	66,529	77,356
Application of Funds	37,248	62,794	64,904	70,754	76,595	80,310	1,32,249	1,37,482

E: MOFSL Estimates, Including GSKCH merged numbers; Goodwill impact will be factored in depending on further clarity post the merger con-call tomorrow

Financials and valuations

Ratios

Y/E March	FY15	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
Basic (INR)								
EPS	16.9	19.3	19.6	24.5	28.1	31.2	34.4	44.2
Cash EPS	18.2	20.7	21.5	26.7	30.5	35.6	39.0	49.1
BV/Share	17.2	29.0	30.0	32.7	35.4	37.2	56.4	58.6
DPS	15.0	15.5	17.0	20.0	22.0	25.0	35.0	44.0
Payout %	90	97	98	99	95	96	102	100
Valuation (x)								
P/E	137.4	120.4	118.1	94.7	82.6	74.3	67.5	52.5
Cash P/E	127.4	111.8	108.0	86.9	76.0	65.2	59.5	47.2
EV/Sales	16.5	16.4	16.0	14.7	13.2	13.0	12.2	10.4
EV/EBITDA	95.7	86.8	82.7	68.5	57.7	51.6	47.3	38.4
P/BV	134.7	79.9	77.3	70.9	65.5	62.4	41.1	39.5
Dividend Yield (%)	0.6	0.7	0.7	0.9	0.9	1.1	1.5	1.9
Return Ratios (%)								
RoE	104.3	83.3	66.5	78.1	82.5	86.0	75.8	76.8
RoCE	158.2	119.8	96.7	108.6	119.1	119.8	103.4	103.5
Working Capital Ratios								
Debtor (Days)	9	13	11	12	16	10	16	16
Asset Turnover (x)	8.1	4.9	4.8	4.8	4.9	4.8	3.3	3.7
Leverage Ratio								
Debt/Equity (x)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Cash Flow Statement

Y/E March	FY15	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
(INR m)								
OP/(loss) before Tax	55,231	59,770	61,550	72,850	85,220	90,920	1,08,838	1,38,461
Financial other income	-3,559	-1,910	-920	-2,800	-770	-1,630	-8,276	-13,029
Depreciation	2,867	3,210	3,960	4,780	5,240	9,380	10,846	11,593
Net Interest Paid	-1,890	-3,160	-2,400	-2,460	-2,950	-3,940	1,047	1,068
Direct Taxes Paid	-17,775	-17,040	-18,040	-21,880	-26,850	-24,650	-28,298	-34,851
(Incr)/Decr in WC	-2,156	-1,130	5,380	8,640	-2,610	2,970	5,934	6,559
CF from Operations	32,719	39,740	49,530	59,130	57,280	73,050	90,091	1,09,802
Other Items	3,506	6,004	450	4,880	4,460	22,660	62,886	20,267
(Incr)/Decr in FA	263	-6,740	-8,520	-8,270	-7,240	-7,020	-1,126	-5,000
Free Cash Flow	32,982	33,000	41,010	50,860	50,040	66,030	88,965	1,04,802
(Pur)/Sale of Investments	1,182	3,290	-9,700	7,790	3,270	22,490	-1,000	-1,000
CF from Invest.	4,951	2,554	-17,770	4,400	490	38,130	60,760	14,267
Dividend Paid	-29,123	-33,420	-35,610	-38,960	-45,460	-62,440	-82,062	-1,03,163
Others	-5,403	-6,660	-7,030	-7,550	-9,160	-4,320	-3,520	-3,520
CF from Fin. Activity	-34,504	-40,080	-42,640	-46,510	-54,620	-66,760	-85,397	-1,06,683
Incr/Decr of Cash	3,166	2,214	-10,880	17,020	3,150	44,420	65,454	17,386
Add: Opening Balance	22,210	25,376	27,590	16,710	33,730	5,750	50,170	1,15,624
Closing Balance	25,376	27,590	16,710	33,730	36,880	50,170	1,15,624	1,33,010

E: MOFSL Estimates

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOFSL is a subsidiary company of Passionate Investment Management Pvt. Ltd.. (PIMPL). MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act") and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company
- received compensation/other benefits from the subject company in the past 12 months
- other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 71934200/ 022-71934263; Website www.motilaloswal.com; CIN no.: L67190MH2005PLC153397; Correspondence Office Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad(West), Mumbai- 400 064. Tel No: 022 7188 1000.

Registration Nos.: Motilal Oswal Financial Services Limited (MOFSL)*: INZ000158836(BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN - 146822; Investment Adviser: INA000007100; Insurance Corporate Agent: CA0579; PMS: INP000006712. Motilal Oswal Asset Management Company Ltd. (MOAMC): PMS (Registration No.: INP000000670); PMS and Mutual Funds are offered through MOAMC which is group company of MOFSL. Motilal Oswal Wealth Management Ltd. (MOWML): PMS (Registration No.: INP000004409) is offered through MOWML, which is a group company of MOFSL. Motilal Oswal Financial Services Limited is a distributor of Mutual Funds, PMS, Fixed Deposit, Bond, NCDs, Insurance Products and IPOs. Real Estate is offered through Motilal Oswal Real Estate Investment Advisors II Pvt. Ltd. which is a group company of MOFSL. Private Equity is offered through Motilal Oswal Private Equity Investment Advisors Pvt. Ltd which is a group company of MOFSL. Research & Advisory services is backed by proper research. Please read the Risk Disclosure Document prescribed by the Stock Exchanges carefully before investing. There is no assurance or guarantee of the returns. Investment in securities market is subject to market risk, read all the related documents carefully before investing. Details of Compliance Officer: Name: Neeraj Agarwal, Email ID: na@motilaloswal.com, Contact No.: 022-71881085.

* MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f August 21, 2018 pursuant to order dated July 30, 2018 issued by Hon'ble National Company Law Tribunal, Mumbai Bench.